Professor Nicholas Latimer

BSc, MSc, PhD

Population Health, School of Medicine and Population Health

Professor of Health Economics

Smiling male member of staff in blue checked shirt
Profile picture of Smiling male member of staff in blue checked shirt
n.latimer@sheffield.ac.uk
+44 114 222 0821

Full contact details

Professor Nicholas Latimer
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
Research interests

My research interests focus on economic evaluation methodology, with a particular emphasis on the incorporation of survival analysis within economic models. I am especially interested in the use of causal inference methods to estimate comparative effectiveness in clinical trials confounded by treatment switching, and in observational (or “Big”, or “Real World”) data.

My past research focused primarily on methods for adjusting survival estimates in the presence of treatment switching - that is, when patients in the control group of a clinical trial switch onto the experimental treatment, thus confounding estimates of the treatment effect (where the relevant question for an economic analysis is what would have happened if control group patients did not receive this experimental treatment).

I am currently undertaking a Senior Research Fellowship funded by Yorkshire Cancer Research. During this Fellowship, my focus is on investigating the use of cancer registry datasets to estimate the comparative effectiveness of cancer treatments used in the NHS.

Read privacy notice (Word, 17.2KB)

I also have an active interest in economic evaluations alongside clinical trials, and particularly the incorporation of value of information analysis in feasibility trials.

Publications

Show: Featured publications All publications

Journal articles

All publications

Journal articles

Conference proceedings papers

  • Latimer N, Taylor K, Hatswell A, Ho S, Okorogheye G, Chen C, Kim I, Borrill J & Bertwistle D (2023) TESTING A SURVIVAL EXTRAPOLATION ALGORITHM FOR CANCER IMMUNOTHERAPIES: PASS OR FAIL?. VALUE IN HEALTH, Vol. 26(12) (pp S13-S13) RIS download Bibtex download
  • Taylor K, Latimer N, Hatswell A, Douglas T, Ho S, Okorogheye G, Borrill J, Chen C, Kim I & Bertwistle D (2023) TREATMENT EFFECT WANING IN IMMUNO-ONCOLOGY HEALTH TECHNOLOGY ASSESSMENTS: A REVIEW OF ASSUMPTIONS AND SUPPORTING EVIDENCE. VALUE IN HEALTH, Vol. 26(12) (pp S365-S365) RIS download Bibtex download
  • Franklin M, Porter A, de Vocht F, Kearns B, Latimer N, Hernandez M, Young T & Kidger J (2023) COMBINING CAUSAL INFERENCE AND WITHIN-TRIAL ECONOMIC EVALUATION METHODS TO ASSESS THE COST-EFFECTIVENESS OF A MENTAL HEALTH SERVICE USING REAL-WORLD DATA: THE QUASI-EXPERIMENTAL ADAPT STUDY. VALUE IN HEALTH, Vol. 26(12) (pp S87-S87) RIS download Bibtex download
  • Gorrod BH, White IR, Mt-Isa S, Hmissi A, Vandormael K, Cappoen N & Latimer N (2023) ADJUSTING FOR SWITCHES TO MULTIPLE TREATMENTS IN RANDOMISED CONTROLLED TRIALS: A COMPARISON OF INVERSE PROBABILITY WEIGHTING AND TWO-STAGE ESTIMATION METHODS. VALUE IN HEALTH, Vol. 26(12) (pp S394-S394) RIS download Bibtex download
  • Xuan J, Mt-Isa S, Latimer N, Yorke-Edwards V, Vandormael K & White IR (2023) EVALUATING BIAS ASSOCIATED WITH INADEQUATE VARIABLE SELECTION WHEN USING INVERSE PROBABILITY OF CENSORING WEIGHTS TO ADJUST FOR TREATMENT SWITCHES IN CLINICAL TRIALS. VALUE IN HEALTH, Vol. 26(12) (pp S423-S424) RIS download Bibtex download
  • Broomfield J, Crowther M, Freeman S, Abrams K, Latimer N & Rutherford MJ (2023) ACCOUNTING FOR STUDY HETEROGENEITY WHEN MODELLING THE MULTI-STATE NATURAL HISTORY OF RARE DISEASES. VALUE IN HEALTH, Vol. 26(12) (pp S421-S422) RIS download Bibtex download
  • Rex S, Chang JY, Bradburn M, Akehurst R & Latimer N (2022) RWD66 Application of the target trial framework for estimating comparative effectiveness using real-world data-a systematic review. Value in Health, Vol. 25(12 Suppl) (pp S461-S461). Vienna, Austria, 6 November 2022 - 9 November 2022. RIS download Bibtex download
  • Kennedy F, Miller N, Roberts A, Beeken RJ, Greenfield D, Potts HWW, Counsell N, Latimer N, Thomas C, Smith L , Gath J et al (2022) Promoting physical activity via a smartphone application in people living with breast, prostate or colorectal cancer: study protocol for a randomised pilot trial (APPROACH). PSYCHO-ONCOLOGY, Vol. 31 (pp 20-20) RIS download Bibtex download
  • Alshreef A, Latimer N, Tappenden P, McKane W, Fotheringham J & Dixon S (2022) A CASE STUDY ASSESSING THE COST-EFFECTIVENESS OF MAINTENANCE IMMUNOSUPPRESSIVE THERAPY FOR KIDNEY TRANSPLANTATION IN ADULTS: ACCOUNTING FOR NON-ADHERENCE USING DATA FROM A RANDOMISED TRIAL AND THE REAL WORLD WITHIN A DECISION-ANALYTIC MODEL. VALUE IN HEALTH, Vol. 25(7) (pp S529-S529) RIS download Bibtex download
  • Alshreef A, Latimer N, Tappenden P, McKane W, Hughes DA & Dixon S (2022) A METHODOLOGICAL FRAMEWORK TO ACCOUNT FOR THE IMPACT OF NON-ADHERENCE ON THE COST-EFFECTIVENESS OF CHRONIC MEDICATIONS. VALUE IN HEALTH, Vol. 25(7) (pp S520-S520) RIS download Bibtex download
  • Rex S, Chang JY, Bradburn M, Akehurst R & Latimer N (2022) Application of the Target Trial Framework for Estimating Comparative Effectiveness Using Real-World Data - A Systematic Review. VALUE IN HEALTH, Vol. 25(12) (pp S461-S461) RIS download Bibtex download
  • Srivastava T, Latimer NR & Tappenden P (2020) ESTIMATION OF TRANSITION PROBABILITIES FOR STATE-TRANSITION MODELS: A REVIEW OF NICE APPRAISALS. VALUE IN HEALTH, Vol. 23 (pp S615-S616) RIS download Bibtex download
  • Amy J-YC, Latimer NR, Gillespie D & Chilcott J (2020) PREVALENCE, CHARACTERISTICS AND KEY ISSUES OF MODELLING TREATMENT SEQUENCES IN HEALTH ECONOMIC EVALUATIONS: A SYSTEMATIC REVIEW OF NICE TECHNOLOGY APPRAISALS. VALUE IN HEALTH, Vol. 23 (pp S606-S606) RIS download Bibtex download
  • Latimer N, White I, Tilling K & Siebert U (2020) ESTIMATING THE TRUE VALUE OF NEW ONCOLOGY TREATMENTS: IMPROVED TWO-STAGE ESTIMATION TO ADJUST FOR TREATMENT SWITCHING IN RANDOMISED TRIALS. MEDICAL DECISION MAKING, Vol. 40(1) (pp E294-E295) RIS download Bibtex download
  • Tai TA, Latimer NR, Benedict Á, Kiss Z & Nikolaou A (2019) PCN150 IMPACT OF USING IMMATURE SURVIVAL DATA ON NICE DECISION-MAKING. Value in Health, Vol. 22 (pp S464-S464) RIS download Bibtex download
  • Fotheringham J, Latimer N, Froissart M, Kronenburg F, Stenvinkel P, Floege J, Eckardt K-U & Wheeler D (2019) FC060THE ASSOCIATION BETWEEN FOUR TIMES A WEEK COMPARED TO THREE TIMES A WEEK HAEMODIALYSIS AND SURVIVAL, HOSPITALISATION AND VASCULAR ACCESS COMPLICATIONS IN EUROPEAN IN-CENTRE PATIENTS. Nephrology Dialysis Transplantation, Vol. 34(Supplement_1) RIS download Bibtex download
  • Fotheringham J, Latimer N, Froissart M, Kronenburg F, Stenvinkel P, Floege J, Eckardt K-U & Wheeler D (2019) THE ASSOCIATION BETWEEN FOUR TIMES A WEEK COMPARED TO THREE TIMES A WEEK HAEMODIALYSIS AND SURVIVAL, HOSPITALISATION AND VASCULAR ACCESS COMPLICATIONS IN EUROPEAN IN-CENTRE PATIENTS. NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol. 34 RIS download Bibtex download
  • Tai TA, Latimer NR, Benedict A, Kiss Z & Nikolaou A (2019) IMPACT OF USING IMMATURE SURVIVAL DATA ON NICE DECISION-MAKING. VALUE IN HEALTH, Vol. 22 (pp S464-S464) RIS download Bibtex download
  • O'Brien S, Cork L, Bandeira V, Bescoby R, Foroni L, Alaily L, Osborne W, Bell-Gorrod H, Latimer N, Apperley J , Hedgley C et al (2018) Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML. Blood, Vol. 132(Supplement 1) (pp 457-457) RIS download Bibtex download
  • Muresan B, Mamolo CM, Cappelleri JC, Mokgokong R, Palaka A, Hills RK, Latimer N & Heeg B (2018) Comparison of Cure Rates between Gemtuzumab Ozogamicin Plus Standard of Care Chemotherapy Vs Standard of Care Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, Vol. 132(Supplement 1) (pp 2712-2712) RIS download Bibtex download
  • Alshreef A, Latimer N, Tappenden P, McKane W, Wong R, Hughes D, Wailoo A, White I, Fotheringham J & Dixon S (2018) Adjusting the causal effects of treatments in the presence of patient non-adherence: a systematic review of methodological papers. European Society for Patient Adherence, Compliance and Persistence, Dublin, 29 November 2018 - 1 December 2018. RIS download Bibtex download
  • Latimer NR (2018) PCN317 - THE CANCER DRUGS FUND: KEY UNCERTAINTIES, DATA COLLECTION PLANS, ANALYTICAL METHODS AND USE OF THE SYSTEMATIC ANTI-CANCER THERAPY (SACT) REAL WORLD DATA SET. Value in Health, Vol. 21 (pp S68-S68) RIS download Bibtex download
  • Thomas SA, Drummond A, Lincoln NB, Palmer R, dasnair R, Latimer N, Hackney G, Hatton R, Walters S, Mandefield L , Cooper C et al (2017) Behavioural activation therapy for depression after stroke (BEADS): a feasibility randomised controlled pilot trial of a psychological intervention for post-stroke depression. INTERNATIONAL JOURNAL OF STROKE, Vol. 12 (pp 15-15) RIS download Bibtex download
  • Bell Gorrod H, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2017) Impact Of Non-Randomised Drop-Out On Treatment Switching Adjustment In The Relapsing-Remitting Multiple Sclerosis Clarity Trial And The Clarity Extension Study. Value in Health, Vol. 20(9) (pp A769-A769) RIS download Bibtex download
  • Bell Gorrod H, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2017) Adjusting for Treatment Switching in the Relapsing-Remitting Multiple Sclerosis Clarity Trial and the Clarity Extension Study. Value in Health, Vol. 20(9) (pp A718-A718) RIS download Bibtex download
  • Latimer N & Abrams KR (2017) TO RE-CENSOR, OR NOT TO RE-CENSOR, THAT IS THE QUESTION: CRITICAL CONSIDERATIONS WHEN APPLYING STATISTICAL METHODS TO ADJUST FOR TREATMENT SWITCHING IN CLINICAL TRIALS. VALUE IN HEALTH, Vol. 20(5) (pp A314-A314) View this article in WRRO RIS download Bibtex download
  • Gorrod BH, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2017) ADJUSTING FOR TREATMENT SWITCHING IN THE RELAPSING-REMITTING MULTIPLE SCLEROSIS CLARITY TRIAL AND THE CLARITY EXTENSION STUDY. VALUE IN HEALTH, Vol. 20(9) (pp A718-A718) RIS download Bibtex download
  • Watkins CL, Latimer N, Wang J & Wright EJ (2016) Guidance On Selecting Appropriate Methods When Considering Adjusting Overall Survival For Treatment Switch In Oncology Studies. Value in Health, Vol. 19(7) (pp A398-A398) RIS download Bibtex download
  • Bell H, Latimer N, Amonkar M & Swann S (2015) Adjusting For Treatment Switching in Rcts – Identifying, Analysing and Justifying Appropriate Methods: a Case Study in Metastatic Melanoma. Value in Health, Vol. 18(7) (pp A338-A338) RIS download Bibtex download
  • Diaz J, Sternberg CN, Mehmud F, Delea TE, Latimer N, Bartlett-Pandite AN & Motzer R (2015) Crossover in oncology clinical trials.. Journal of Clinical Oncology, Vol. 33(15_suppl) (pp e15592-e15592) RIS download Bibtex download
  • Bell H, Latimer N, Amonkar M & Casey M (2014) Adjusting for Treatment Crossover in A Trametinib Metastatic Melanoma Rct: Identifying the Appropriate Method. Value in Health, Vol. 17(7) (pp A577-A577) RIS download Bibtex download
  • Latimer N, Amonkar M, Stapelkamp C & Sun P (2014) Abstract CT330: Adjusting for confounding effects of treatment crossover in a randomized phase 2 study of dabrafenib plus trametinib inBRAFV600+ metastatic melanoma. Clinical Trials RIS download Bibtex download
  • Boucher R, Abrams KR, Crowther MJ, Lambert PC, Wailoo AJ & Latimer NR (2013) ADJUSTING FOR TREATMENT SWITCHING IN CLINICAL TRIALS WHEN ONLY SUMMARY DATA ARE AVAILABLE - AN EVALUATION OF POTENTIAL METHODS. VALUE IN HEALTH, Vol. 16(7) (pp A610-A611) RIS download Bibtex download
  • Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2013) A GUIDE TO ADJUSTING SURVIVAL TIME ESTIMATES TO ACCOUNT FOR TREATMENT SWITCHING IN RANDOMISED CONTROLLED TRIALS. VALUE IN HEALTH, Vol. 16(7) (pp A325-A325) RIS download Bibtex download
  • Latimer N, Abrams KR, Amonkar M, Stapelkamp C & Swann RS (2013) Adjusting for treatment crossover in the BREAK-3 metastatic melanoma trial for dabrafenib: Preliminary analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15) RIS download Bibtex download
  • Abrams KR, Latimer N, Amonkar M, Stapelkamp C, Casey M & Grp T (2013) Adjusting for treatment crossover in the METRIC metastatic melanoma (MM) trial for trametinib: Preliminary analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15) RIS download Bibtex download
  • Paracha N, Davies A, Latimer N, Parker C, Mealing S, Scott D, Padhiar A, Schulpher M & Wang Q (2013) The importance of adjusting for treatment crossover bias in oncology clinical trials: An analysis of the EGF104900 trial in metastatic breast cancer (mBC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15) RIS download Bibtex download
  • Latimer N, Lambert P, Crowther M, Abrams KR, Wailoo AJ & Morden JP (2012) METHODS FOR ESTIMATING SURVIVAL BENEFITS IN THE PRESENCE OF TREATMENT CROSSOVER: A SIMULATION STUDY. VALUE IN HEALTH, Vol. 15(7) (pp A462-A462) RIS download Bibtex download
  • Latimer N (2011) METHODS FOR EXTRAPOLATING SURVIVAL DATA USED IN NICE TECHNOLOGY APPRAISALS: INCONSISTENCIES AND LIMITATIONS. VALUE IN HEALTH, Vol. 14(7) (pp A242-A242) RIS download Bibtex download
  • Rowen D, Mulhern B, Brazier J, Jacoby A, Marson T, Latimer N, Snape D, Baker G & Hughes D (2010) Using the Liverpool Quality of Life battery to develop a health state classification system for Epilepsy. QUALITY OF LIFE RESEARCH, Vol. 19 (pp 57-57) RIS download Bibtex download
  • Gyldmark M, Gatzemeier U, Nicolson M, Latimer N & Walzer S (2008) EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UNITED KINGDOM. VALUE HEALTH, Vol. 11(6) (pp A357-A357) RIS download Bibtex download
  • Ducournau P, Latimer N, Sabate E & Walzer S (2008) EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE. VALUE HEALTH, Vol. 11(6) (pp A471-A472) RIS download Bibtex download
  • Latimer N & Lewis G (2008) The cost of adults with severe active rheumatoid arthritis who do not respond to treatment following treatment with one TNF inhibitor. RHEUMATOLOGY, Vol. 47 (pp II123-II124) RIS download Bibtex download
  • Somerville M, Scott D, Hancock M, Geary U & Latimer N (2008) The impact of rituximab on resource use in a UKNHS rheumatology day care service. RHEUMATOLOGY, Vol. 47 (pp II119-II120) RIS download Bibtex download
  • Latimer N & Lewis G (2008) What are the costs of treating severe active rheumatoid arthritis with TNF inhibitors, rituximab and abatacept?. RHEUMATOLOGY, Vol. 47 (pp II122-II123) RIS download Bibtex download
  • Latimer NR & Lewis GJ (2005) A cost utility analysis of peginterferon alfa-2a (40KD) versus peginterferon alfa-2b (12KD) for the treatment of chronic hepatitis C (CHC) in the UK. VALUE HEALTH, Vol. 8(6) (pp A58-A58) RIS download Bibtex download

Reports

  • Chang J-YA, Chilcott JB & Latimer NR (2024) Leveraging real-world data to assess treatment sequences in health economic evaluations: a study protocol for emulating target trials using the English Cancer Registry and US Electronic Health Records-Derived Database View this article in WRRO RIS download Bibtex download
  • Latimer N & Pollard D (2019) Pre-read document 1: Challenges in valuing and paying for combination regimens in oncology View this article in WRRO RIS download Bibtex download
  • Latimer NR, White IR, Abrams KR & Sieburt U (2017) Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times? View this article in WRRO RIS download Bibtex download
  • Latimer NR, Abrams KR, Lambert PC, Crowther MJ & Morden JP (2014) Assessing methods for dealing with treatment crossover in clinical trials: A follow-up simulation study View this article in WRRO RIS download Bibtex download

Scholarly editions

  • Mulhern B, Rowen D, Brazier J, Jacoby A, Marson T, Snape D, Hughes D, Latimer N & Baker GA (2010) Developing a health state classification system from NEWQOL for epilepsy using classical psychometric techniques and Rasch analysis: a technical report. RIS download Bibtex download

Posters

  • Bell H, Latimer N, Amonkar M & Casey M Adjusting for treatment crossover in a trametinib metastatic melanoma RCT: Identifying the appropriate method. RIS download Bibtex download

Other

  • Palmer R, Cooper C, Enderby P, Brady M, Julious S, Bowen A, Latimer N, Gossage-Worrall R, Cross E & Harrison M (2018) Big CACTUS study protocol v5.0 31may17. RIS download Bibtex download

Preprints

Teaching interests

My teaching interests lie in the field of health economics, economic evaluation and survival analysis. I have previously co-ordinated and taught several modules on economic evaluation and survival analysis on various MSc courses. Currently, I teach methods for adjusting for treatment switching in clinical trials on the Further Statistical Methods for Health Economic Analysis module on the Health Economics and Decision Modelling MSc.

I have completed the Certificate in Learning and Teaching (PGCertHE), the University Of Sheffield's professional development course in learning and teaching in higher education.

I am currently supervising five PhD students. Abu Alshreef is investigating adjustment for non-adherence in economic evaluation. Rachid Rafia is exploring multi-state models and partitioned survival models for cancer treatments. Amy Chang is researching methods for modelling the effectiveness and cost-effectiveness of treatment sequences. Ash Bullement is investigating survival analysis methods. Saleema Rex is examining the use of causal inference methods to estimate comparative effectiveness using registry datasets.

I am interested in supervising potential students on topics around adjustment for treatment switching in clinical trials, and the use of causal inference methods to estimate comparative effectiveness from observational datasets.

Professional activities and memberships

I have pursued my research interests through a series of research fellowships. In 2012 I completed an NIHR Doctoral Research Fellowship, and in 2018 I completed an NIHR Post-Doctoral Research Fellowship. My current 5-year Yorkshire Cancer Research Fellowship began in January 2019. I also contribute to several other research and consultancy projects in ScHARR.

  • I am a member of NICE Technology Appraisal Committee B
  • I have been a member of the Yorkshire and Humber Research for Patient benefit Programme Regional Advisory committee
  • I am a member of the Health Economists Study Group
  • I am a Fellow of the Higher Education Academy
  • I have been an invited expert for the NICE Scientific Advice Programme.
Downloads